Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

To join this study, your doctor will need to check some things. You'd likely be considered if you've had anti-MAG neuropathy for five years or less, and your condition has clearly worsened in the last two years. You'll also need to have a specific type of abnormal protein in your blood, and nerve tests showing a particular kind of nerve damage.

Additionally, your anti-MAG levels in your blood need to be quite high. There are also specific rules about not having had certain other treatments recently, like immunoglobulin or strong immune-suppressing medicines. You may not be able to join if you've had a severe allergic reaction to similar medicines, have certain other health problems like serious heart, kidney, or liver conditions, or if you've been treated with rituximab before.

Taking part in this study would involve regular visits to the clinic. You would either receive rituximab through a drip (infusion) or a placebo, which looks like the active drug but has no medicine in it. You wouldn't know which one you're getting, and neither would your study doctor. Before the infusion, you would also receive other medications to help prevent any reactions. The study would involve several assessments to check your nerve function, daily ability, and general health over time. There would also be follow-up appointments after your treatment period. The total duration of your involvement in the study would be determined by the study design, but generally, these trials last for several months to a couple of years.